（於開曼群島註冊成立的有限公司） （股份代號：3883） 董事名單與其角色和職能 中國奧園集團股份有限公司董事會（「董事會」）成員載列如下： 執行董事 鄭少輝先生 蔣展鴻先生 史莉莉女士 非執行董事 郭梓文先生 Mr. Mohamed Obaid Ghulam Badakkan Alobeidli （董事會主席） 張國強先生 李鏡波先生 黃煒強先生 董事會設立三個董事會轄下委員會。各董事會成員在該等委員會中所擔任之職位載列如下： 審核委員會 張國強先生 （主席） 李鏡波先生 黃煒強先生 1 薪酬委員會 獨立非執行董事 2 李鏡波先生 （主席） 張國強先生 黃煒強先生 史莉莉女士 提名委員會 黃煒強先生 （主席） 張國強先生 李鏡波先生 鄭少輝先生 史莉莉女士 香港，二零二六年一月十六日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 於本公告日期及除上文所披露者外，(i)史女士於本公告日期前三年並無在於香港或海外的其他上 市公司中擁有任何其他主要委任及資格或擔任董事職務；(ii)史女士並無於本公司或本集團成員公 司中擔當任何其他職位；(iii)史女士與本公司任何董事、高級管理人員、主要或控股股東（具有上 市規則所賦予其之涵義）並無任何關係；(iv)史女士並無於證券及期貨條例（香港法例第571章）第XV 部所界定的本公司任何股份、相關股份或債權證中擁有權益；及(v)概無有關史女士獲調任而須根 據上市規則第13.51(2)(h)至13.51(2)(v)條之規定予以披露的其他資料，亦無須敦請本公司股東垂注 的任何其他事宜。 董事會就史女士於本公司之新職務致賀。 董事調任 及 董事委員會成員變動 本公告由中國奧園集團股份有限公司（「本公司」，連同其附屬公司，統稱為「本集團」）根據香港聯合 交易所有限公司（「香港聯交所」）證券上市規則（「上市 ...

Core Viewpoint - The Hong Kong Stock Exchange has criticized and taken disciplinary action against Xingyue Kanglv (formerly known as Aoyuan Health) and China Aoyuan, along with 15 directors from both companies, for violating listing rules through improper financial assistance transactions that occurred around 2021 [3][4]. Group 1: Disciplinary Actions - Xingyue Kanglv and its subsidiary provided financial assistance to China Aoyuan and its subsidiaries, violating listing rules [3]. - Key figures involved include Guo Zining, who was identified as the main orchestrator of the fund transfers, and Chen Zhibin, who facilitated these transactions [4]. - A total of 33 billion RMB was transferred through 147 transactions from January 1, 2021, to March 31, 2022, primarily as short-term loans [3][5]. Group 2: Internal Investigations and Findings - Following the revelation of the fund transfers, both companies suspended trading on April 1, 2022, and established independent investigation committees [5]. - The investigations uncovered significant deficiencies in internal controls, including the management of conflicts of interest and approval processes [5]. - Despite the financial assistance, China Aoyuan did not recover from its debt issues, and Xingyue Kanglv faced a decline in revenue by approximately 13% and a core net profit drop of over 41% in the first half of 2025 [5].

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has criticized and condemned a past violation involving financial "blood transfusions" between Xingyue Kanglv (formerly known as Aoyuan Health) and China Aoyuan, along with disciplinary actions against 15 directors of both companies [1][2]. Group 1: Disciplinary Actions - Xingyue Kanglv and its subsidiary, referred to as "Xingyue Group," provided financial assistance to China Aoyuan and its subsidiaries, violating the Listing Rules [1]. - The disciplinary actions include reprimands for Xingyue Kanglv and its former chairman, CEO, and non-executive director, as well as for China Aoyuan's former vice chairman and CEO [1][2]. - A total of 33 billion RMB was transferred from Xingyue Group to Aoyuan Group through 147 transactions between January 1, 2021, and March 31, 2022, primarily as short-term loans [1]. Group 2: Key Individuals Involved - Guo Zining is identified as the main architect behind the fund transfers, prioritizing the interests of China Aoyuan over those of Xingyue Kanglv, which led to significant liquidity pressure on Xingyue Kanglv [2]. - Chen Zhibin, the former CFO of China Aoyuan, facilitated the fund transfers and approved 118 out of the 147 transactions, failing to manage conflicts of interest [2]. - Zheng Wei, a former executive director of Xingyue Kanglv, approved 122 transactions without exercising independent judgment or seeking board approval [2]. Group 3: Consequences and Investigations - Following the revelation of the fund transfers, both companies were suspended from trading on April 1, 2022, and established independent committees to investigate the matter [3]. - The investigation revealed significant deficiencies in internal controls regarding related party transactions and conflict management [3]. - Despite attempts to alleviate China Aoyuan's debt issues, the financial strain severely impacted Xingyue Kanglv, which reported a 13% decline in revenue and over 41% drop in core net profit in its mid-2025 report [3].

Core Viewpoint - The Hong Kong Stock Exchange has condemned Star Health Travel Holdings Limited and several of its directors for failing to comply with listing rules, particularly regarding financial assistance provided to its parent company, China Aoyuan Group, amidst liquidity issues [1][2][3] Group 1: Disciplinary Actions - The Hong Kong Stock Exchange issued a statement condemning multiple directors from Star Health Travel and China Aoyuan for their roles in the violations, including Mr. Guo Zining, Mr. Chen Zhibin, and Mr. Zheng Wei [1] - Specific directors have been mandated to complete training hours, with Mr. Guo Zining and others required to complete 17 hours, while others, including Mr. Ruan Yongxi and Dr. Li Zijun, must complete 26 hours [2] Group 2: Financial Assistance Violations - Star Health Travel provided 3.3 billion RMB in financial assistance to China Aoyuan without adhering to the listing rules, which is a significant breach [2] - Between January 1, 2021, and March 31, 2022, Star Health Travel engaged in 147 transactions to provide this financial support, despite being aware of China Aoyuan's liquidity issues [2] Group 3: Director Responsibilities - The violations were attributed to the failure of the directors to fulfill their responsibilities, particularly in seeking board approval and ensuring compliance with listing rules [3] - Mr. Guo Zining and Mr. Chen Zhibin were noted as the main planners of the financial assistance, prioritizing China Aoyuan's interests over those of Star Health Travel [3] - Other directors, while not directly approving the transactions, failed to act in the best interests of Star Health Travel, indicating a lack of adequate internal controls [3]

Group 1 - Hong Kong Stock Exchange condemned Star Health Group Co., Ltd. (formerly known as Aoyuan Health Life Group Co., Ltd.) and several of its directors for failing to fulfill their duties, leading to investor rights violations [1][3] - The case involves Star Health providing RMB 3.3 billion in financial assistance to its then-listed parent company, China Aoyuan, without adhering to the Listing Rules [2] - The violations were attributed to directors not seeking board approval for significant transactions, despite being aware of China Aoyuan's liquidity issues and the financial pressure on Star Health [3] Group 2 - Specific directors, including Guo Zining, Chen Zhibin, and Zheng Wei, were identified as having approved transactions without proper oversight, prioritizing China Aoyuan's interests over those of Star Health [3] - Other directors, although not directly involved in approving the transactions, failed to act in the best interests of Star Health, indicating a lack of adequate internal controls [3] - The Hong Kong Stock Exchange mandated training hours for several directors as part of the disciplinary actions taken against them [1][3]

香港聯合交易所有限公司 (香港交易及結算所有限公司全資附屬公司) THE STOCK EXCHANGE OF HONG KONG LIMITED (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited) 譴責： 紀律行動聲明 (1) 星悅康旅股份有限公司（前稱奧園健康生活集團有限公司）（星悅康旅）； 聯交所對以下各方作出紀律行動： 制裁及指令 香港聯合交易所有限公司（聯交所） 譴責： 向下列人士作出： 董事不適合性聲明及譴責： (2) 星悅康旅前主席、行政總裁及非執行董事以及中國奧園集團股份有限公司（中國奧 園）前副主席、行政總裁及執行董事郭梓寧先生； 損害投資者權益聲明及譴責： …/2 • 星悅康旅股份有限公司（前稱奧園健康生活集團有限公司）（股份 代號：3662）；及 • 星悅康旅股份有限公司及／或中國奧園集團股份有限公司（股份代 號：3883）15 名董事 (3) 星悅康旅前非執行董事以及中國奧園前首席財務官及執行董事陳志斌先生; (4) 星悅康旅前執行董事鄭煒先生（鄭先生）； 批評： (16) 中國奧園獨立非執行董事 ...

本月底法定/註冊股本總額： HKD 1,000,000,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 中國奧園集團股份有限公司 截至月份: 2025年12月31日 狀態: 新提交 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03883 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：3883） 解決不發表意見一事的計劃及措施的 落實進展 茲提述中國奧園集團股份有限公司（「本公司」）截至二零二四年十二月三十一日止年度的年報（「年 報」）及本公司日期為二零二五年七月四日及二零二五年九月三十日的公告（統稱「該等公告」）。除另 有界定者外，本公告所用詞彙與年報及該等公告所界定者具有相同涵義。 承董事會命 中國奧園集團股份有限公司 執行董事 鄭少輝 本公司謹此提供有關解決不發表意見一事的計劃及措施的進一步落實進展。直至本公告日期計劃 及措施的落實情況概述如下： 1 (i) 本集團正積極推動本集團境內債務的全面重組，以建立緩解債務壓力的長效機制，並強化全 週期現金流風險管控體系，保障本集團的經營安全。目前境內債務重組計劃方案已經基本完 善，正在徵求各方（包括境內債權人）意見，本公司將在獲得實質性進展時及時進行公告； (ii) 本集團一直與各境內貸款 ...

Group 1 - The company, China Aoyuan (03883), announced the issuance of 104,900 new shares as a result of the conversion of mandatory convertible bonds due in 2028, which were issued on March 20, 2024 [1]